Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GPC3 Targeted CAR-T Cell Therapy in Advanced GPC3 Expressing Solid Tumor Malignancies
NCT05003895Phase 1Recruiting
- Sponsor
- National Cancer Institute
- Start
- Dec 2021
- Primary completion
- Dec 2026
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of BOXR1030 in hepatocellular carcinoma (HCC) and solid tumor (2 arms), sponsored by National Cancer Institute. Primary endpoint: Safety and feasibility of T-cells expressing anti-GPC3 chimeric antigen receptor at 15 years. Started Dec 2021; status: recruiting.
02
Drugs
BOXR1030
03
Conditions
hepatocellular carcinoma (HCC)solid tumor
Beyond the preview
Go deeper on NCT05003895.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05003895.